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Lung cancer claims the highest mortality 
and the second most new cases in the US. 
Cisplatin, the first platinum-based 
anticancer drug, has the highest potency 
against lung cancer but carries many severe 
adverse effects. Miriplatin was discovered 
with a higher lipophilicity and approved in 
Japan for the treatment of hepatocellular 
carcinoma (HCC). Nanocarriers provide a 
promising platform to overcome the 
physiochemical barrier of solid tumors and 
to reduce the toxicity of anticancer drugs. 
In this study, miriplatin is formulated into 
various lipid-based nanocarriers (micelles 
and solid lipid nanoparticles (SLNs)) by a 
scale-up preparation method to evaluate 
the anticancer activities against lung cancer.
Figure 2 shows that the miriplatin-loaded nano 
formulations (both micelles and SLNs) were 
successfully prepared by the co-solvent slow 
evaporation method.
Figure 3 compares the two types of nano formulations,  
micelles were much smaller (~10 nm in diameter) and 
more homogeneous (PDI < 0.3), while SLNs were 
bigger (~ 100 nm in diameter) and more 
heterogeneous (PDI ~0.8). Both nano formulations 
showed high platinum recovery (>75%). The TEM 
images shows that micelles had a morphology of 
spherical dots at around 10 nm in diameter, while SLNs 
showed spherical structures with a size distribution 
from 50 to 150 nm. 
Figure 4 highlights that a 3D MCS model of A549-iRFP 
cells with fluorescent signals was successfully 
established. Selected miriplatin-loaded nano 
formulations showed substantial anticancer activity 
against A549-iRFP 3D MCS, which is comparable to 
cisplatin, a first line drug against lung cancer. The 
fluorescent signals indicated that the cancer cells did 
not relapse after the clearance of the anticancer 
agents after three-day exposure. 
Miriplatin-loaded nano formulations were 
prepared by a scale-up method (co-solvent 
slow evaporation). (Figure 2)
Selected miriplatin-loaded formulations 
prepared by co-solvent slow evaporation 
method were characterized by sizes, 
polydispersity index (PDI), platinum 
recovery and morphology using 
transmission electron microscopy (TEM).
A three-dimensional multicellular spheroid 
(3D MCS) model of A549-iRFP cells was 
well established for in vitro evaluation of 
the nano formulations’ anticancer activity 
against lung cancer. The A549-iRFP 3D MCS 
were treated by 3-day exposure to 
miriplatin-loaded nano formulations and 
4-day drug-free growth.
A co-solvent slow evaporation method has been 
established as a pharmaceutically viable scale-up 
method to prepare nano formulations with good 
reproducibility. 
The miriplatin-loaded nano formulations carrying 
favorable physiochemical properties (smaller size, high 
platinum drug recovery and round morphological 
features) could enhance the anticancer activities of 
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Figure 1: Proposed mechanism of action of miriplatin-loaded nano formulations. (a) The passive targeting of miriplatin-loaded nano 
formulation to lung solid tumor; (b) The cellular uptake of miriplatin-loaded nano formulation in lung solid tumor cells.
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Figure 3: Composition, size, PDI and Pt recovery of selected 
miriplatin-loaded nano formulations (table), and 
morphology of miriplatin-loaded micelles (3a) and SLNs (3b).
Figure 2: Schematic of preparation of miriplatin-loaded nano 
formulations by co-solvent slow evaporation method.
Figure 4: Morphology of A549-iRFP 3D MCS (4a). Cell viability 
(4b) and fluorescent signals change (4c) of A549-iRFP 3D 
MCS after exposure to miriplatin-loaded nano formulations.
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